KR102863233B1 - 멀미에서의 트라디피탄트의 용도 - Google Patents

멀미에서의 트라디피탄트의 용도

Info

Publication number
KR102863233B1
KR102863233B1 KR1020207022180A KR20207022180A KR102863233B1 KR 102863233 B1 KR102863233 B1 KR 102863233B1 KR 1020207022180 A KR1020207022180 A KR 1020207022180A KR 20207022180 A KR20207022180 A KR 20207022180A KR 102863233 B1 KR102863233 B1 KR 102863233B1
Authority
KR
South Korea
Prior art keywords
tradipitant
pharmaceutical composition
motion sickness
composition according
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207022180A
Other languages
English (en)
Korean (ko)
Other versions
KR20210067980A (ko
Inventor
미하엘 에이치. 폴리머로풀로스
Original Assignee
반다 파마슈티칼즈, 인코퍼레이티드.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 반다 파마슈티칼즈, 인코퍼레이티드. filed Critical 반다 파마슈티칼즈, 인코퍼레이티드.
Priority to KR1020257030873A priority Critical patent/KR20250140634A/ko
Publication of KR20210067980A publication Critical patent/KR20210067980A/ko
Application granted granted Critical
Publication of KR102863233B1 publication Critical patent/KR102863233B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
KR1020207022180A 2018-09-28 2019-09-26 멀미에서의 트라디피탄트의 용도 Active KR102863233B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257030873A KR20250140634A (ko) 2018-09-28 2019-09-26 멀미에서의 트라디피탄트의 용도

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862737992P 2018-09-28 2018-09-28
US62/737,992 2018-09-28
US201962874927P 2019-07-16 2019-07-16
US62/874,927 2019-07-16
PCT/US2019/053107 WO2020069092A1 (en) 2018-09-28 2019-09-26 Use of tradipitant in motion sickness

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257030873A Division KR20250140634A (ko) 2018-09-28 2019-09-26 멀미에서의 트라디피탄트의 용도

Publications (2)

Publication Number Publication Date
KR20210067980A KR20210067980A (ko) 2021-06-08
KR102863233B1 true KR102863233B1 (ko) 2025-09-22

Family

ID=68165866

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207022180A Active KR102863233B1 (ko) 2018-09-28 2019-09-26 멀미에서의 트라디피탄트의 용도
KR1020257030873A Pending KR20250140634A (ko) 2018-09-28 2019-09-26 멀미에서의 트라디피탄트의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020257030873A Pending KR20250140634A (ko) 2018-09-28 2019-09-26 멀미에서의 트라디피탄트의 용도

Country Status (20)

Country Link
US (2) US20220249444A1 (https=)
EP (2) EP3856338B1 (https=)
JP (1) JP7468964B2 (https=)
KR (2) KR102863233B1 (https=)
CN (1) CN111918701B (https=)
AU (1) AU2019348001B2 (https=)
BR (1) BR112020015484A2 (https=)
CA (1) CA3089238A1 (https=)
CL (1) CL2020002165A1 (https=)
DK (1) DK3856338T3 (https=)
ES (1) ES3010832T3 (https=)
FI (1) FI3856338T3 (https=)
HR (1) HRP20250097T1 (https=)
HU (1) HUE070000T2 (https=)
IL (1) IL281569B2 (https=)
MX (1) MX2020008456A (https=)
PT (1) PT3856338T (https=)
SI (1) SI3856338T1 (https=)
WO (1) WO2020069092A1 (https=)
ZA (1) ZA202004594B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2824552T3 (es) * 2015-03-04 2021-05-12 Vanda Pharmaceuticals Inc Método de tratamiento con tradipitant
JP7791832B2 (ja) 2020-03-26 2025-12-24 バンダ・ファーマシューティカルズ・インコーポレイテッド トラジピタントによる下気道感染症の治療
WO2023019084A1 (en) * 2021-08-12 2023-02-16 Vanda Pharmaceuticals Inc. Treatment of gastric accommodation with tradipitant
US20240350469A1 (en) 2021-08-31 2024-10-24 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
AU2023413130A1 (en) 2022-12-21 2025-06-05 Vanda Pharmaceuticals Inc. Methods of treatment with tradipitant

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1035115E (pt) * 1999-02-24 2005-01-31 Hoffmann La Roche Derivados de 4-fenilpiridina e a sua utilizacao como antagonistas do receptor nk-1
AU2003230829B8 (en) * 2002-04-26 2008-12-11 Eli Lilly And Company Triazole derivatives as tachykinin receptor antagonists
BRPI0415010B8 (pt) * 2003-10-24 2021-05-25 Lilly Co Eli formas cristalinas iv e v de {2-[1-(3,5-bis-trifluorometilbenzil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il)-(2-clorofenil)-metanona, (2-clorofenil)-[2-(2-hidróxi-2-piridin-4-il-vinil)piridin-3-il]metanona, seus processos de preparação, e composição farmacêutica sólida
EP2722045B1 (en) * 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
ES2824552T3 (es) * 2015-03-04 2021-05-12 Vanda Pharmaceuticals Inc Método de tratamiento con tradipitant
CN119074729A (zh) * 2017-11-17 2024-12-06 万达制药公司 使用川地匹坦治疗胃肠疾病的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of Veterinary Pharmacology and Therapeutics 31.3 (2008): 220-229*

Also Published As

Publication number Publication date
JP2022511194A (ja) 2022-01-31
JP7468964B2 (ja) 2024-04-16
EP3856338B1 (en) 2024-11-06
CL2020002165A1 (es) 2021-01-04
HRP20250097T1 (hr) 2025-03-28
CN111918701B (zh) 2024-08-02
BR112020015484A2 (pt) 2021-04-27
EP3856338A1 (en) 2021-08-04
NZ766397A (en) 2023-09-29
KR20250140634A (ko) 2025-09-25
ES3010832T3 (en) 2025-04-04
CA3089238A1 (en) 2020-04-02
EP4450126A3 (en) 2025-02-19
SI3856338T1 (sl) 2025-04-30
US20240285588A1 (en) 2024-08-29
US20220249444A1 (en) 2022-08-11
IL281569A (en) 2021-05-31
HUE070000T2 (hu) 2025-04-28
AU2019348001A1 (en) 2020-08-06
AU2019348001B2 (en) 2023-09-21
EP4450126A2 (en) 2024-10-23
PT3856338T (pt) 2025-01-31
FI3856338T3 (fi) 2025-02-03
IL281569B2 (en) 2025-04-01
IL281569B1 (en) 2024-12-01
ZA202004594B (en) 2024-12-18
WO2020069092A1 (en) 2020-04-02
DK3856338T3 (da) 2025-02-10
CN111918701A (zh) 2020-11-10
MX2020008456A (es) 2020-09-25
KR20210067980A (ko) 2021-06-08

Similar Documents

Publication Publication Date Title
KR102863233B1 (ko) 멀미에서의 트라디피탄트의 용도
US20210008037A1 (en) Use of tradipitant in motion sickness
Tattersall et al. The novel NK1 receptor antagonist MK–0869 (L–754,030) and its water soluble phosphoryl prodrug, L–758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets
KR102864285B1 (ko) 트라디피탄트를 이용한 위장 질환의 치료 방법
CN111479592B (zh) 阿片样物质使用障碍、阿片样物质戒断症状和慢性疼痛的治疗
US20220096449A1 (en) Method of treatment with tradipitant
EP3251699B1 (en) Composition comprising methylphenidate and ondansetron for use in substance-related disorders
RU2808669C2 (ru) Применение традипитанта от укачивания
US20240299373A1 (en) Improved use of tradipitant in motion sickness
Jermain et al. Pharmacotherapy of obsessive‐compulsive disorder
KR20110053356A (ko) 불안 장애의 치료
NZ766397B2 (en) Use of tradipitant in motion sickness
Kyles et al. An evaluation of combined immunosuppression with MNA 715 and microemulsified cyclosporine on renal allograft rejection in mismatched mongrel dogs
US20090176857A1 (en) Use of Organic Compounds
Blier et al. Present and future tools to improve the antidepressant response based on the differential properties of 5-HT receptor subtypes
Tamminga et al. The development of (−)-3PPP as an Antipsychotic drug
Chamey Double-blind study on the effect of pindolol addition to accelerate the antidepressant response
Carlsson Stabilizing action of partial dopamine receptor agonists in psychosis
POHAR Sustained-Release (SR) Bupropion

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

A18 Application divided or continuation or continuation in part accepted

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A18-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)